Hims & Hers built a $2.35 billion telehealth platform by marketing stigmatized health categories directly, then faced national backlash when that same directness collided with FDA scrutiny. The publicly traded company (NYSE: HIMS) generated approximately $2.35 billion in 2025 revenue, up 59% year over year, and projects $3.1 to $3.3 billion for 2026, according to its Q2 2026 earnings release. Its marketing model depends on normalizing categories legacy CPG and pharma brands treat as clinical or embarrassing.
What makes Hims & Hers' marketing model different from traditional CPG?
Hims & Hers sells hair loss, sexual health, mental health, dermatology, and weight loss treatment through direct telehealth relationships rather than retail intermediaries. The company reported nearly 2.9 million subscribers as of Q2 2026, up 19% year over year, according to its earnings release. Its marketing strategy treats stigma itself as the primary obstacle to purchase, using plain language and direct naming of conditions instead of aspirational or clinical framing.
Why it works: categories like hair loss and sexual health carry purchase hesitation rooted in embarrassment, not price or awareness, so removing friction from the conversation removes the barrier to conversion. The company's Hers brand, which includes weight loss and dermatology offerings, grew to represent over 40% of U.S. revenue in Q2 2026, up from approximately 35% a year earlier, per the same filing.
How did the 2025 Super Bowl ad turn Hims & Hers' strategy into a liability?
Hims & Hers aired a 60-second Super Bowl ad titled "Sick of the System" in February 2025, calling obesity "America's deadliest epidemic" and criticizing the $160 billion weight loss industry while promoting its own compounded semaglutide, according to reporting by ABC News. The ad drove a 650% spike in app traffic and ranked fifth in engagement among all Super Bowl ads that year, per data from EDO Inc. cited by Fierce Healthcare.
The same directness that drove engagement drew regulatory scrutiny. Senators Dick Durbin and Roger Marshall sent a letter to the FDA raising concerns that the ad promoted an unapproved compounded drug without disclosing side effects, according to MobiHealthNews. The Obesity Society publicly objected to the ad's imagery, and Northeastern University communications professor Elizabeth Glowacki told reporters the ad created a false impression that patients did not need medical supervision.
Why it works (or fails): an advertising strategy built on stigma removal works until the category being destigmatized is a regulated medical treatment, where the same plain-spoken tone that builds trust in consumer categories can read as medical advice without a clinician attached. Hims & Hers defended the ad publicly, with a company representative telling reporters, "it's not about the ad, it's about the message."
How is Hims & Hers scaling its model internationally?
The company acquired ZAVA, a European digital pharmacy platform, in July 2025, followed by Livewell in November 2025 to establish Hims & Hers Canada. A pending acquisition of Eucalyptus, announced February 2026, would extend the platform into Australia, Japan, and additional European markets. Management said in its Q1 2026 investor presentation that international markets are positioned to scale past $1 billion in annual revenue within three years.
Why it works: each acquisition buys an existing regulatory and pharmacy infrastructure rather than building one from scratch per country, compressing the multi-year process of securing telehealth prescribing rights market by market. The company's long-term target, disclosed in its financial guidance, is $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.
What should other CPG and health brands take from the Hims & Hers case?
Directness earns trust in stigmatized categories, but the same tone that works for hair loss or mental health carries different regulatory weight in prescription medication. Any brand marketing a compounded or off-label product should assume advertising claims will be read by regulators, not only by customers. International scale is faster through acquiring existing licensed infrastructure than through building it market by market.
Hims & Hers shows that stigma-reduction marketing can build a multibillion-dollar platform, but the same directness draws regulatory scrutiny once the product is a medication.
Hims & Hers generated approximately $2.35 billion in 2025 revenue, up 59% year over year, and reported $753 million in Q2 2026 revenue, up 38% year over year. The company raised its full-year 2026 guidance to $3.1 to $3.3 billion.
Why was the 2025 Super Bowl ad controversial?
The ad promoted a compounded, non-FDA-approved version of semaglutide without disclosing side effects or risks, drawing objections from the Obesity Society, health communication researchers, and a letter from Senators Dick Durbin and Roger Marshall to the FDA.
Is Hims & Hers a public company?
Yes. Hims & Hers Health, Inc. trades on the NYSE under the ticker HIMS.
How is Hims & Hers expanding internationally?
Through acquisitions: ZAVA in Europe (July 2025), Livewell for Canada (November 2025), and a pending deal for Eucalyptus (announced February 2026) to extend into Australia, Japan, and additional European markets. Hims & Hers shows that stigma-reduction marketing can build a multibillion-dollar platform, but the same directness draws regulatory scrutiny once the product is a medication.
Written by
EPR Editorial Team
The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era — built to be cited by the AI engines that now answer the question. Publishing since 2009.
